Low-Dose Alteplase No Better for Acute Ischemic Stroke

Share this content:
Low-Dose Alteplase No Better for Acute Ischemic Stroke
Low-Dose Alteplase No Better for Acute Ischemic Stroke

MONDAY, Oct. 2, 2017 (HealthDay News) -- For key demographic subgroups of patients with acute ischemic stroke (AIS), low-dose alteplase does not differ from standard-dose alteplase in terms of treatment effects on death or disability, according to a study published online Oct. 2 in JAMA Neurology.

Xia Wang, Ph.D., from the University of New South Wales in Australia, and colleagues conducted a prespecified secondary analysis of the international Enhanced Control of Hypertension and Thrombolysis Stroke Study clinical trial of low- versus standard-dose intravenous alteplase for patients with AIS. A total of 3,310 patients with a clinical diagnosis of AIS, confirmed by brain imaging, were included in the alteplase-dose arms; participants were randomized to receive low- or standard-dose alteplase. A total of 3,297 patients were included in the analysis.

The researchers found that there were no significant differences between low- and standard-dose alteplase in the treatment effects for poor outcomes (death or disability) by age, ethnicity, or severity (all P > 0.37 for interaction). The treatment effects of low- versus standard-dose alteplase on functional outcome was consistent for Asians and non-Asians (P = 0.32 for interaction). The reductions in rates of symptomatic intracerebral hemorrhage were generally consistent with low-dose alteplase, although the reduction was not significant by age, ethnicity, or severity.

"Further investigation is required to identify patients with AIS who may benefit from low-dose alteplase," the authors write.

Several authors disclosed financial ties to the pharmaceutical and medical device industries.

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease


Sign up for myCME e-newsletters


More in Home

Older Adults Less Likely to Have Provider-Ordered Flu Testing

Older Adults Less Likely to Have Provider-Ordered Flu ...

Presence of influenza-like illness, younger age independently predict provider-ordered testing

Nutrients in Child's First 1,000 Days Key for Neurodevelopment

Nutrients in Child's First 1,000 Days Key for ...

Nutrition in prenatal period and first two years of life affects prenatal nutrient delivery, child development

In-Office Angiolytic Laser Effective for Vocal Polyps

In-Office Angiolytic Laser Effective for Vocal Polyps

Fewer adverse events for patients treated with laser plus concurrent polypectomy than laser alone

is free, fast, and customized just for you!

Already a member?

Sign In Now »